Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy.

ABSTRACT:

Introduction

Health-related quality of life (HRQoL) is an important part of the clinical assessment and management of psoriasis. Few studies have investigated the effects of withdrawing treatment on the relationship between HRQoL and objective clinical manifestations of psoriasis. This post hoc subanalysis of a clinical trial (REVEAL) examined the relationship of HRQoL [assessed with the Dermatology Life Quality Index (DLQI)] and objective disease activity [assessed with the Psoriasis Area and Severity Index (PASI)] among patients before and after they underwent protocol-mandated discontinuation of psoriasis therapy.

Methods

Adult patients with moderate-to-severe plaque psoriasis who received adalimumab from baseline and had 75% or greater improvement in the PASI score at we

SUBMITTER: Poulin Y 

PROVIDER: S-EPMC4065279 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature